New Approaches for the Identification and Characterization of Functional Markers of the Risk of Extension of Breast Cancer Without Lymph Node Involvement
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT02926547
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
1. Identify the tissue proteins associated with early breast cancer invasion phases without lymph node involvement .
2. Consider their role in the invasion and the risk of tumor spread .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 108
Inclusion Criteria
- Breast cancer
- CCIS
- Invasive tumors
- Breast cancer tissues available in the biobank
Exclusion Criteria
- non availability of cancer tissue specimen
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A list of the ten proteins most associated with early breast cancer invasion phases without lymph node involvement . Day 0 The primary objective of this study is to Identify the tissue proteins associated with early breast cancer invasion phases without lymph node involvement. The outcome is a list of identified proteins.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What tissue proteins are associated with early breast cancer invasion without lymph node involvement in NCT02926547?
How do identified functional markers in NCT02926547 correlate with tumor spread risk in node-negative breast cancer?
Are there specific molecular pathways targeted by functional markers in early breast cancer invasion as studied in NCT02926547?
What biomarkers for patient selection emerge from NCT02926547's observational study of breast cancer progression?
How does the protein profile from NCT02926547 compare to other biomarker studies in non-metastatic breast cancer?